Tumor endothelial cells (ECs) promote cancer progression in ways beyond their role as conduits supporting metabolism. However, it is unknown how vascular niche-derived paracrine factors, defined as angiocrine factors, provoke tumor aggressiveness. Here, we show that FGF4 produced by B cell lymphoma cells (LCs) through activating FGFR1 upregulates the Notch ligand Jagged1 (Jag1) on neighboring ECs. In turn, upregulation of Jag1 on ECs reciprocally induces Notch2-Hey1 in LCs. This crosstalk enforces aggressive CD44 + IGF1R + CSF1R + LC phenotypes, including extranodal invasion and chemoresistance. Inducible EC-selective deletion of Fgfr1 or Jag1 in the Em-Myc lymphoma model or impairing Notch2 signaling in mouse and human LCs diminished lymphoma aggressiveness and prolonged mouse survival. Thus, targeting the angiocrine FGF4-FGFR1/Jag1-Notch2 loop inhibits LC aggressiveness and enhances chemosensitivity.
INTRODUCTION
Vascular endothelial cells (ECs) are a specialized component of the tumor microenvironment that can orchestrate tumor growth and invasion (Beck et al., 2011; Bergers and Hanahan, 2008; Butler et al., 2010a; Calabrese et al., 2007; Carmeliet and Jain, 2011; Charles et al., 2010; Ghajar et al., 2013; Lu et al., 2013; Weis and Cheresh, 2011) . During regeneration, tissue-specific ECs provide instructive paracrine cues, known as angiocrine growth factors, that trigger proliferation of repopulating progenitor cells (Brantley-Sieders et al., 2011; Butler et al., 2010a Butler et al., , 2010b Butler et al., , 2012 Ding et al., 2014 Ding et al., , 2010 Ding et al., , 2011 Ding et al., , 2012 Potente et al., 2011; Red-Horse et al., 2007) . However, the mechanism by which EC-derived angiocrine factors influence tumor behaviors is unknown (Gilbert and Hemann, 2010; Leite de Oliveira et al., 2012; Nakasone et al., 2012; Schmitt et al., 2000) .
Notch signaling is a pivotal modulator of lymphomagenesis (Aster et al., 2008; Espinosa et al., 2010; Liu et al., 2010; Lobry et al., 2013) , enhancing Myc activity and upregulating receptors such as insulin growth factor-1 receptor (IGF1R) (Medyouf et al., 2011; Weng et al., 2006) . The Jagged (Jag) and Delta-like (Dll) families of Notch ligands induce Notch signaling (Gridley, 2010; Siekmann and Lawson, 2007) . Both Jag1 and Dll4 are preferentially expressed by ECs during tumor progression but have
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Blood vessels within lymphomas are not just passive conduits delivering nutrients but contain specialized ECs that constitute a maladapted niche actively instigating aggressiveness during tumor progression. Here, we show that tumor ECs supply angiocrine factors to promote chemotherapy resistance and extranodal invasiveness of CD44 + IGF1R + CSF1R + LCs. LCs produce FGF4 to induce expression of Notch ligand Jag1 in ECs. In turn, EC-derived angiocrine Jag1 activates Notch2 in LCs to promote tumor invasiveness and chemoresistance. Interfering with the FGF4/Jag1 cross-talk between LCs and ECs decreases tumor progression and promotes sensitivity to chemotherapy, thereby increasing survival of tumor-bearing mice. Targeting protumorigenic angiocrine factors supplied by lymphoma blood vessels promises efficacious approaches to block tumorigenesis and restore chemotherapy sensitivity without compromising tumor blood perfusion.
distinct roles in neoplastic tissue (Rehman and Wang, 2006; Sethi et al., 2011; Vilimas et al., 2007) . Dll4 is expressed by sprouting ECs and appears to regulate EC expansion (proliferative angiogenesis), whereas juxtacrine activation of Notch receptors on tumor cells appears to be mediated by EC-derived Jag1 (inductive angiogenesis) (Lu et al., 2013; Sonoshita et al., 2011; Noguera-Troise et al., 2006; Ridgway et al., 2006) . However, mechanisms controlling expression of these Notch ligands in tumor ECs are undefined (Benedito et al., 2009; Corada et al., 2010; High et al., 2008; Hoey et al., 2009; Hofmann et al., 2010; Tung et al., 2012) . Moreover, the paucity of ECspecific mouse genetic models has handicapped elucidation of the EC-derived angiocrine signals regulating the fate and behavior of tumors. Malignant lymphoma cells (LCs) are composed of heterogeneous cell subpopulations, with a subset of LCs possessing more aggressive features (Dierks et al., 2007; Hoey et al., 2009; Kelly et al., 2007) . Although chemotherapy eliminates the majority of proliferating LCs, a subpopulation of aggressive LCs manifests resistance, ultimately leading to lymphoma relapse. Because the surrounding microenvironment can support tumor cells (Hanahan and Coussens, 2012; Lane et al., 2009; Memarzadeh et al., 2007; Rakhra et al., 2010; Reimann et al., 2010; Scadden, 2012; Trimboli et al., 2009; Zhang et al., 2012) , we reasoned that elucidating the microenvironmental signals (i.e., tumor vascular niche) influencing aggressive LCs, such as lymphoma initiating cells (LICs), could provide effective lymphoma treatment strategies.
RESULTS

ECs Support Expansion of LCs with Aggressive Features
To identify the crosstalk between ECs and LCs without the confounding influence of supplementation with exogenous serum and angiogenic growth factors, we devised a serumand growth factor-free platform to propagate LCs in coculture with ECs. To this end, we transduced ECs, such as human umbilical vein ECs, with the adenoviral E4ORF1 gene. E4ORF1 transduced ECs (VeraVec ECs)-for simplicity referred to here as ECs-are nontransformed but have low-level Akt signaling that permits their serum-free survival while retaining their tissue-specific vascular attributes as well as the capacity to form functional contact-inhibited monolayers in vitro and perfused, patent blood vessels in vivo (Butler et al., 2010b (Butler et al., , 2012 Nolan et al., 2013; Seandel et al., 2008) . Indeed, because maintenance of VeraVec ECs does not require recombinant angiogenic factors (e.g., vascular endothelial growth factor A (VEGF-A) and fibroblast growth factor 2 (FGF2)), serum, or other xenobiotic factors, these ECs can be used in coculture models to screen and to identify the instructive vascular niche-like functions and angiocrine factors supporting the expansion of organ-specific stem and progenitor cells (Butler et al., 2010b; Ding et al., 2010 Ding et al., , 2011 Ding et al., , 2014 (Hanahan and Weinberg, 2011; Medyouf et al., 2011) (Figure 1I ; Table S1 ). Flow cytometry analysis and quantitative PCR (qPCR) confirmed that EC coculture-mediated upregulation of corresponding proteins was due to generation of a CD44 + IGF1R + CSF1R + LC subset ( Figures 1J, S1F , and S1G).
To assess the functional activity of the CD44 + IGF1R + CSF1R + subpopulation, we obtained clonally derived LCs by serial dilution in coculture with ECs ( Figure 1K) Figure 1I ). qPCR confirmed specific upregulation of Hey1 in LC EC ( Figure 2A) (Ding et al., 2010) (Figure 2H ). Knockdown of Notch2 or Hey1 or administration of compound E significantly reduced hepatic tumor load, but Notch1 knockdown had little effect ( Figures 2I, 2 -K, S2K, and S2L). Thus, juxtacrine activation of Notch2-Hey1 by ECs promotes extranodal invasion, a feature of aggressive lymphomas.
Although ECs express several Notch ligands, Jag1 was primarily upregulated by ECs after coculture with LCs ( Figure 2L ). This finding implicates EC Jag1 as the ligand activating Notch2 in LCs because LCs express negligible Jag1 ( Figure S2M Figures 3G-3N and S3G-S3J).
Notably, after intrasplenic injection into NSG mice, human LC EC induced Jag1 expression in the ECs surrounding the lymphoma nodules but not tumor-free hepatic regions ( Figure 3O ). Thus, expansion of invasive human Burkitt's LCs is also driven by instructive angiocrine factors supplied by the vascular niche.
LCs Induce FGFR1 Signaling in ECs to Prime a Jag1 + Vascular Niche that Reciprocally Reinforces Lymphoma Propagation and Chemoresistance We have found that during organ regeneration, activation of VEGF-A/VEGFR2 and FGF/FGF receptor 1 (FGFR1) signaling in ECs induces expression of angiocrine factors (Ding et al., 2010 (Ding et al., , 2011 (Ding et al., , 2014 ). Hence, we tested whether LCs might coopt these mechanisms to upregulate Jag1 in tumor ECs and form a malignant vascular niche. Both microarray expression and qPCR analysis showed that coculture with ECs upregulated FGF4 in mouse and human LCs ( Figure 4A ). Whereas normal human lymph nodes have negligible FGF4, we found significant expression of FGF4 protein in human Burkitt's lymphoma tissue and preferential activation of FGFR1 in the lymphoma-associated ECs ( Figure S4A ). To examine whether FGFR1-mediated signaling in ECs was necessary for Jag1 induction, we exposed control ECs and FGFR1-deficient ECs to serum-free or conditioned media (CM) derived from LCs. CM derived from mouse LC EC activated Jag1 expression in ECs in a FGFR1-dependent manner (Figures 4B and 4C) . Notably, during EC-LC coculture, shRNA knockdown of FGFR1 in ECs or of FGF4 in LCs blocked Jag1 induction and FGFR1 signaling in ECs (Figures 4D and S4B-S4D). Importantly, after intrasplenic injection, FGF4-deficient human LCs failed to upregulate Jag1 in the ECs of liver lymphoma nodules of recipient mice ( Figure 4E ). Therefore, LCs supply FGF4 to activate FGFR1 on ECs to reinforce Jag1--mediated vascular niche function, driving Notch2-dependent expansion of aggressive LCs. To determine whether this ''feed-forward'' loop drives lymphoma tumorigenesis in vivo, we conditionally deleted Fgfr1 specifically in adult ECs by crossing VE-cadherin-Cre ERT2 mice with Fgfr1 loxP/loxP mice ( Figure 4F ) and using tamoxifen to delete Fgfr1 specifically in ECs (Fgfr1 iDEC/iDEC ) ( Figures S4E and S4F ). To control for Cre-mediated toxicity, we used EC-specific haplodeficient Fgfr1 iDEC/+ mice as control mice. We used a murine B6RV2 lymphoma transplantation model to examine the lymphoma growth. Fgfr1 iDEC/iDEC mice, but not Fgfr1 iDEC/+ mice, were inhospitable to subcutaneously and intrasplenically injected B6RV2 LCs, resulting in reduced tumor growth and hepatic colonization ( Figures 4G-4K ). Therefore, activation of FGFR1 in ECs is required for LCs to establish a protumorigenic vascular niche. We next crossed Em-Myc mice with Fgfr1 iDEC/iDEC and control mice ( Figure 5A ) to assess the role of FGFR1 in establishing a See also Figure S1 and Table S1 .
Cancer Cell
Tumor Vascular Niche Induces Aggressive Lymphoma Figure 5I ). LCs treated with doxorubicin upregulated FGF4 expression, enabling a vascular niche that confers chemoresistance to LCs ( Figure 5J ). Hence, FGFR1-mediated signaling deploys Jag1 in tumor ECs, establishing a protumorigenic vascular niche that shelters resident LCs from chemotherapy-induced cytotoxicity.
Endothelial Jag1 in Tumor Capillaries Subverts Indolent LCs to Manifest Aggressive Features
To investigate whether enhanced chemoresistance and invasiveness of LCs upon being cocultured with Jag1 + ECs were due to selective enrichment of an aggressive LC subclone or bestowing aggressive attributes to indolent LCs by tumorigenic vascular niche, we cocultured clonally derived CD44
À LCs (triple-negative LCs) with ECs ( Figure 6A ).
After coculture with ECs, the triple-negative LC progeny acquired $14-fold greater MCF capacity ( Figures 6B and 6C ). Immunophenotypic analysis showed that 9.5% of LCs from the single triple-negative clone are CD44 + IGF1R + after being cocultured with EC ( Figure 6D ). Notably, after EC coculture, triple-negative LCs were more lethal to NSG mice following intraperitoneal (i.p.) injection ( Figure 6E ). All of these effects were attenuated by coculture with Jag1-deficient ECs (Figures 6B-6E) . Therefore, the aggressive lymphoma tumor phenotype is conferred upon LCs by angiocrine signals emanating from a tumorigenic vascular microenvironment.
We then assessed tumorigenicity and extranodal invasiveness of LCs in Jag1 iDEC/+ control and Jag1 iDEC/iDEC mice ( Figure 6F ). LCs transplanted into Jag1 iDEC/iDEC mice yielded smaller tumors than did the same LCs inoculated into Jag1 iDEC/+ mice (Figures 6G and 6H; Figure S5A ). To test whether host EC Jag1 altered CD44
À LCs in vivo, individual triple-negative LC clones were injected subcutaneously into Jag1
Jag1
iDEC/+ ( Figure 6I ), or WT mice ( Figure S5B ). Following expansion in the recipient mice, transplanted triple-negative LCs acquired over 6-fold greater triple-positive immunophenotype and $5-fold higher MCF in Jag1 iDEC/+ mice than in Jag1 iDEC/iDEC mice ( Figure 6J ). Therefore, host EC-derived Jag1 subverts indolent LCs to manifest aggressive phenotypes. Figure 8B ; Figure S6A ). Moreover, Figures 8E and 8F) . Notably, when EC Jag1 is intact, a subset of perivascularly localized LCs with activated Notch signaling (reported by TNR-GFP cells) was protected from doxorubicininduced cell death. Therefore, Jag1-expressing ECs establish a chemoresistant microenvironment for LCs via juxtacrine Notch activation ( Figure 8G ). To assess whether aberrant EC Jag1 expression could cause vascular abnormalities that might compromise tumor blood supply, we examined vascular perfusion in Myc See also Figure S2 .
Deletion of Jag1 in ECs of
Cancer Cell
Tumor Vascular Niche Induces Aggressive Lymphoma The properties of the malignant vascular niche are co-opted via activation of FGF4/FGFR1 signaling in tumor ECs. This signaling induces host ECs to express Jag1 in proximity to neighboring LCs. Importantly, the FGFR1-Jag1 feed-forward signaling loop promotes LC chemoresistance and is further reinforced by chemotherapy administration. In this way, angiocrine Jag1 functionalizes a chemoresistance niche that activates Notch signaling in perivascular LCs and spares them from chemotherapeutics such as doxorubicin. These results suggest a paradigm of tumor propagation whereby a dynamic neoplasmprimed tumor microenvironment shelters tumor cells from chemotherapy and instructively directs them to grow locally and invade distal organs. Thus, targeting the malignant vascular niche should sensitize LCs to chemotherapy and improve outcomes.
Indeed, EC-specific deletion of Fgfr1 or Jag1 in the Fgfr1 iDEC/iDEC and Jag1 iDEC/iDEC mice enhanced chemosensitivity and improved mouse survival by abolishing Notch activation in Myc + LCs after doxorubicin treatment. Similarly, in human lymphoma specimens, we found Jag1 upregulated in tumor ECs and the Notch pathway activated in perivascular human LCs, as originally observed in the murine lymphoma models. These findings highlight the functional interplay between ECs and tumor cells that depends on the FGF-Notch paracrine/juxtacrine loop. Upregulation of endothelial Jag1 is central to this loop because it endows both mouse and human LCs with aggressive LC features. Similarly, as-yet unrecognized and distinct angiocrine pathways are likely activated within the microenvironment of other tumor types. Blockade of Jag1 expressed by tumor ECs reduced lymphoma progression without compromising perfusion of the tumor vasculature. Jag1 appeared dispensable for most homeostatic vascular functions because deletion of endothelial Jag1 in adult mice caused no excess mortality or morbidity. Thus, inhibiting the instructive angiocrine signals from a tumor-primed vascular niche can effectively target aggressive LC features. Anti-angiocrine therapeutics need not interfere with tumor perfusion and therefore should not be compromised by tumor hypoxia and rebound angiogenesis that can lead to paradoxical tumor growth (Ebos et al., 2009; Pà ez-Ribes et al., 2009) .
Comparative analyses of human and mouse lymphoma tissues suggest that our findings may have clinical relevance. Jag1 is upregulated in ECs in human lymphoma specimens. Jag1 upregulation in ECs endows both mouse and human LCs with aggressive LC features. Whether induced expression of Jag1 and activation of Notch pathway in human tumor ECs may also portend poor prognosis is unknown and can only be determined in double-blind multicenter clinical studies. Based on our data, we speculate that patients harboring tumors with the capacity of inducing functional Notch ligands in tumor ECs may be at higher risk for tumor relapse and chemoresistance and be treated with more aggressive therapeutic protocols.
Taken together, our findings demonstrate that tumor cells prime a maladapted vascular niche that reciprocally confers tumors with aggressive, lethal properties: augmenting tumor growth, fostering chemoresistance, and promoting extranodal invasion. Indeed, function of lymphoma-propagating or -initiating cells depends on the protumorigenic state of the vascular niche and cannot be entirely attributed to cell-autonomous malignant properties of tumor cells. For example, an authentic tumor-initiating cell may fail to engraft host tissues with an inhospitable vascular niche, and assays used to identify tumor-initiating cells need to be modified to account for the activation state of vascular niche. Similarly, differences in host EC functions may underlie the tumor tropisms that select common metastatic sites. This study introduces promising therapeutic approaches to improve clinical outcomes for patients with aggressive lymphomas by ejecting LCs from the protumorigenic vascular niche to limit local tumor growth and extranodal invasion while sensitizing LCs to chemotherapy.
EXPERIMENTAL PROCEDURES
Transgenic Reporter and Gene-Targeted Animals Jag1 loxP/loxP mice were provided by Dr. Thomas Gridley (Jackson Laboratories), and Fgfr1 loxp/loxp mice were obtained from Dr. Michael Simons (Yale University School of Medicine). Generation of inducible EC-specific Fgfr1 knockout mice was carried out as described (Ding et al., 2010 (Ding et al., , 2011 Wang et al., 2010) . In brief, Fgfr1 loxp/loxp or Jag1 loxp/loxp mice were bred with VE-cadherin-Cre ERT2 (cdh5-PAC-Cre ERT2 ) transgenic mice and treated (K-N) Inhibition of Notch1, Notch2, and Hey1 was performed in human LCs before EC coculture, and EC-dependent expansion (K and L) and hepatic tumor load of (M and N) of LCs were determined; n = 4. Scale bars, 1000 mm in (K) and 50 mm in (M).
(O) Jag1 expression in host ECs within the hepatic lymphoma nodule was assessed 14 days after intrasplenic injection of human LCs into NSG mice. Lymphoma mass in the liver is denoted by a dotted line. Scale bar, 50 mm (20 mm in inset). See also Figure S3 and Table S2 . Table S2 . Human Burkitt's LCs without Epstein-Barr-virus infection were purchased from American Type Culture Collection (ATCC).
In Vitro Modeling of Vascular Niche for LC Coculture
To maintain EC survival in serum/growth factor-free conditions without confounding effects of supplementation with serum, bovine brain extracts and recombinant angiogenic factors (i.e., VEGF-A, FGF2, epidermal growth factors, PDGFs, and angiopoietins); primary freshly purified ECs, such as human umbilical vein ECs; or adult tissue-specific mouse ECs were transduced with E4ORF1 gene (VeraVec ECs; Angiocrine Bioscience). VeraVec ECs maintain their native vascular and microvascular attributes and produce physiological levels of tissue-specific angiocrine factors (Butler et al., 2010b (Butler et al., , 2012 Nolan et al., 2013; Seandel et al., 2008 (F) Different LC colonies were transplanted into mice with EC-specific deletion of Jag1 (Jag1 iDEC/iDEC ). Jag1 iDEC/+ mice were used as control. 
CSF1R
À LCs after transplantation to control and Jag1 iDEC/iDEC mice. LCs were isolated at day 28 after subcutaneous injection from enlarging tumor mass and analyzed for CD44, IGF1R, and CSF1R (I) and serial colony formation capacity (J). Each derived clone was injected into three mice. See also Figure S5 . of LCs was performed as described (Ding et al., 2010) . Briefly, the mice were anesthetized, and 5 3 10 5 mCherry-labeled human LCs or 1 3 10 5 mouse LCs were injected into the parenchyma of the spleen. Splenectomy was carried out after the injection. The mice were sacrificed 14 days after intrasplenic transplantation, and hepatic tumor load was analyzed by hematoxylin and eosin (H&E) staining and immunofluorescence whole scan of liver lobe. g-secretase inhibitor compound E was utilized to abolish Notch pathway activation in LCs. LCs were incubated with 1 mM compound E. For in vivo Notch inhibition, compound E was i.p. injected to mice at 2 mg/kg. Notch2 activation was also determined as described in Supplemental Experimental Procedures.
Cancer Cell
Flow Cytometric Analysis of LCs
For flow cytometry analysis, LCs were filtered through a 30 mm strainer, preblocked with Fc block (CD16/CD32; BD Biosciences), and then incubated with the primary antibodies CD44, CD19, and B220 (eBiosciences); IGF1R (Abcam); and Notch1 and Notch2 (Biolegend). Primary antibodies were conjugated to Alexa Fluor dyes using antibody labeling kits (Invitrogen) following the instructions of the manufacturer. GFP-expressing cells were detected by their own fluorescence, as described in Supplemental Experimental Procedures.
Immunofluorescent Staining
For immunofluorescence study, cryopreserved sections were incubated with antibodies to mouse VE-Cadherin (R&D Systems), Jag1 (Abcam), and Ki67 (Dako) supplemented with 10% normal donkey serum/1% BSA/0.1% Tween 20, followed by incubation with fluorophore-conjugated second antibodies (Jackson ImmunoResearch). Images were captured on AxioVert LSM710 microscope (Zeiss).
Methylcellulose Colony Assay
Mouse and human LCs formed colonies upon serum culture (LC Serum ) or EC coculture (LC EC ). Single colonies of LC Serum and LC EC were dispersed in methylcellulose. Colonies formed were randomly picked and serially passaged. Colony number was quantified upon each serial passage.
Statistical Analysis of Data
All data are presented as means ± SEM. Comparisons between different groups were made using Student's t test and ANOVA. Statistical significance was considered as p < 0.05.
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